Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
Significance When oxygen availability becomes limited, organs and cells activate the hypoxic response to generate energy. This response releases a large amount of lactate into the circulation as a result of anaerobic glycolysis. However, we found that activating the hypoxic response in the liver by inhibiting the oxygen sensor prolyl hydroxylase domain containing protein 2 (PHD2) enhances the uptake of lactate for gluconeogenesis, also known as the Cori cycle, and ameliorates lactic acidosis. Our findings suggest that PHD2 serves as a viable drug target for the treatment of life threatening lactic acidosis, which is frequent complication of severe infectious and ischemic diseases, as well as of biguanide treatment in patients with diabetes with renal failure. Loss of prolyl hydroxylase 2 (PHD2) activates the hypoxia inducible factor dependent hypoxic response, including anaerobic glycolysis, which causes large amounts of lactate to be released from cells into the circulation. We found that Phd2 null mouse embryonic fibroblasts (MEFs) produced more lactate than wild type MEFs, as expected, whereas systemic inactivation of PHD2 in mice did not cause hyperlacticacidemia. This unexpected observation led us to hypothesize that the hypoxic response activated in the liver enhances the Cori cycle, a lactate glucose carbon recycling system between muscle and liver, and thereby decreases circulating lactate. Consistent with this hypothesis, blood lactate levels measured after a treadmill or lactate tolerance test were significantly lower in Phd2 liver specific knockout (Phd2 LKO) mice than in control mice. An in vivo 13C labeled lactate incorporation assay revealed that the livers of Phd2 LKO mice produce significantly more glucose derived from 13C labeled lactate than control mice, suggesting that blockade of PHD2 in the liver ameliorates lactic acidosis by activating gluconeogenesis from lactate. Phd2 LKO mice were resistant to lactic acidosis induced by injection of a lethal dose of lactate, displaying a significant elongation of survival. Moreover, oral administration of a PHD inhibitor improved survival in an endotoxin shock mice model. These data suggest that PHD2 is a potentially novel drug target for the treatment of lactic acidosis, which is a serious and often fatal complication observed in some critically ill patients.
Proceedings of the National Academy of Sciences